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Abstract
The development of therapeutic monoclonal antibodies (mAbs) can be hin-
dered by their tendency to aggregate throughout their lifetime, which can illicit
immunogenic responses and render mAb manufacturing unfeasible. Conse-
quently, there is a need to identifymAbswith desirable thermodynamic stability,
solubility, and lack of self-association. These behaviors are assessed using an
array of in silico and in vitro assays, as no single assay can predict aggregation
and developability. We have developed an extensional and shear flow device
(EFD), which subjects proteins to defined hydrodynamic forces which mimic
those experienced in bioprocessing. Here, we utilize the EFD to explore the
aggregation propensity of 33 IgG1 mAbs, whose variable domains are derived
from clinical antibodies. Using submilligramquantities ofmaterial per replicate,
wide-ranging EFD-induced aggregation (9-81% protein in pellet) was observed
for thesemAbs, highlighting the EFD as a sensitivemethod to assess aggregation
propensity. By comparing the EFD-induced aggregation data to those obtained
previously from 12 other biophysical assays, we show that the EFD provides
distinct information compared with current measures of adverse biophysical
behavior. Assessing a candidate's liability to hydrodynamic force thus adds novel
insight into the rational selection of developable mAbs that complements other
assays.
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1 INTRODUCTION
Protein aggregation is a major problem for the biopharmaceutical industry.1-3 Therapeutically, the presence of aggre-
gates may not only reduce efficacy,4 but can also cause adverse immune responses in vivo.5-7 Protein aggregation also
poses significant challenges for the large-scale manufacture of protein therapeutics,8-10 a sector currently dominated
by monoclonal antibodies (mAbs).11 Aggregation can occur at any stage of a mAb's lifetime including: cell culture,12,13
purification,9,14,15 formulation,16,17 transportation18 and storage.19 Aggregation can thus be a major impediment to the
successful translation of a candidate mAb to a commercial therapeutic. Consequently, the detection of aggregates,20-23
their removal during processing9,24,25 and their general suppression,1,17,26,27 has been of intense interest to academics,
drug manufacturers and regulators alike. As many hundreds of sequences are generally identified during a discovery
and affinity maturation campaign,28 so-called “developability” assays,29,30 are commonly deployed to aid identification
of those sequences with the biophysical properties that facilitate platform manufacturing.
Two main approaches have emerged to identify developable and manufacturable sequences. First, in silico algo-
rithms can be used to identify aggregation-prone regions (APRs) or insoluble regions within a mAb sequence or
structure, for example, Structural Aggregation Propensity,31,32 AGGRESCAN-3D,33 CamSol,34-36 and Solubis.26,37 Sec-
ond, a plethora of in vitro assays has been developed which probe the different biophysical properties of a mAb, such
as: biolayer interferometry38 and self-interaction nanoparticle spectroscopy39 to probe self-association; cross-interaction
chromatography40 or the use of polyspecificity reagent41 to detect cross-association; dynamic light scattering42 and
standup monolayer adsorption chromatography43 to assess colloidal stability; as well as various spectroscopic methods
to determine conformational stability.44,45 The existence of so many methods highlights the fact that no one assay is able
to identify the specific aggregation-prone sequences that drive aggregation, especially from partially unfolded states.46
Furthermore, the ability of these methods to predict long-term stability remains unclear47,48 and, until recently, the
relationship between these techniques was unknown.49
In an attempt to identify the design rules (akin to Lipinski's rule of five for small molecules50) and to understand the
degeneracy (if any) between commonly used developability assays,Wittrup and colleagues used an array of 12 biophysical
methods to interrogate the biophysical properties of 137 clinically relevant antibodies. These molecules were constructed
by grafting the variable domain sequences of the parent molecules into a common IgG1 scaffold, enabling direct compar-
ison of the sequences in common solution conditions.51 At the time of the study, 48 of these molecules were derived from
approved mAbs, 42 from Phase III and 47 from Phase II. Through statistical analysis of the dataset, reinforced by direct
experimental comparison of nine of the grafted IgG1s with their clinical parent molecules, they found that approved
mAbs generally possessed more “desirable” biophysical properties, while those that had reached Phase-II clinical trial (at
the time of the study) generally possessed more “red flags” (biophysical behaviors deemed undesirable using a numerical
threshold) than their approved counterparts.51 A key finding of this work was that developability assays could be divided
into five distinct groups that report on: (i) nonspecific interactions using ELISA (eg, Baculovirus Particle [BVP] assay52),
(ii) polyspecific- or self-interaction (eg, affinity capture self-interaction nanoparticle spectroscopy [AC-SINS]53), (iii) loss
of monomer at elevated temperature, (iv) hydrophobicity (eg, hydrophobic interaction chromatography [HIC]54), and (v)
the expression and thermal stability of a mAb (eg, titer from transient expression in HEK293 cells).51
To date, most developability assays investigate undesirable posttranslational modifications, thermal stability and
specific or nonspecific interactions of the native state of a candidatemAb.30 It is becoming clear, however, thatmany aggre-
gation pathways initiate from activated, partially unfoldedmetastable states thatmay not be detected by these techniques,
especially in accelerated stability assays.19,55,56 To address this issue, we previously developed a device that exerts hydro-
dynamic forces, similar to those applied during bioprocessing,9,57,58 onto proteins.159-61 In this method, fluid is passed
between two syringes coupled via a narrow glass capillary (one fifteenth of the syringes' diameter) (Figure 1A).
The presence of a constriction generates an extensional flow field, followed by a shear flow field (Figure 1A), with
these fluid fields applying hydrodynamic forces to the proteins contained within. We used this apparatus, termed the
extensional flow device (EFD), to understand at a fundamental level how extensional flow induces protein aggregation
through partial unfolding of proteins and demonstrated that aggregation of mAbs can be triggered by flow at concentra-
tions as low as 0.5mgmL−1.59 In addition, we showed that a candidate mAb with poor biophysical and pharmacokinetic
properties (MEDI1912_WFL) wasmore sensitive to hydrodynamic flow (in terms of quantity of aggregate produced) than
its derivative (MEDI1912_STT), rationally engineered to improve its biophysical characteristics.62 Finally, we used the
EFD to identify which factors (protein concentration, sequence, buffer components, and flow conditions) are key to mod-
ulating the flow-induced aggregation of three model IgG1 mAbs.60 These data show the utility of hydrodynamic force
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F I GURE 1 Overview of flow-induced aggregation and its quantification. (A) Schematic of the EFD (i) 0.5mL of protein solution is
driven from one syringe to the other by a stepper motor. (ii) The two syringes are connected by a borosilicate glass capillary. The abrupt
reduction in the cross-sectional area of the flow path between the syringe and capillary (15:1) generates an extensional flow (strain
rate = 11 750 s−1). (iii) Computational Fluid Dynamics profiles (inset) show the rapid velocity increase of the fluid from the syringe through
the capillary from 8mms −1 to 1.9m s−1 (capillary wall shear rate = 52 000 s−1) (top), preceded by the extensional flow region (bottom). The
sample then enters the second syringe chamber, prior to passage through the device in the reverse direction. (B) To quantify the effect of
extensional flow, stressed, and quiescent control protein solutions are clarified by ultra-centrifugation (30min at 35 000g). Fifty microliters of
the resulting supernatant and the pellet (with 50 μL supernatant above it to prevent disturbing the pellet) are dissolved overnight in buffer
containing 6M guanidine hydrochloride (GdnHCl). The fraction pelleted protein is then quantified using UV-absorbance spectroscopy as
described (Methods). Source: Part figure A is adapted from Reference 60 under a CC BY 4.0 license
as a potential developability assay. As these studies used only three IgG1 mAbs,59,60,62 our understanding of the behav-
ior of a broader range of therapeutic mAbs, or how the EFD relates to other methods of assessing aggregation, remained
unknown.
To address these outstanding questions, we describe herein the hydrodynamic flow-induced aggregation of 33 mAbs
selected from the Jain et al dataset of 137 isotype-matched IgG1s under common solution conditions.51 We show that the
selected mAbs exhibit varied aggregation behavior in response to hydrodynamic stress and that this behavior cannot be
predicted using currently available in silico methods. Finally, through statistical comparison of the EFD data with those
of the other assays for this dataset, we show that the EFD reveals distinct biophysical information aboutmAbs that cannot
be obtained from other assays. The EFD thus provides the user with unique information on the sensitivity of a mAb to
hydrodynamic stress, which could aid the development, formulation or selection ofmAb sequencesmost likely to succeed
in a development pipeline.
2 MATERIALS AND METHODS
2.1 Protein sample selection and preparation
The 137 mAbs of the complete Jain et al dataset had previously been clustered into groups of mAbs that exhibited sim-
ilar biophysical behaviors in the assays utilized.51 In selecting the subset of 33 proteins to be used here, it was ensured
that the minimized dataset contained representatives from each cluster, weighted to reflect their respective sizes (15
from Cluster 1, six from Cluster 2 and four from each of Clusters 3, 4, and 5). The resulting set thus represents the
overall spread of protein biophysical behavior observed previously (Supplementary Table I and Figure S1).51 The 33
Adimab protein samples, referred to as (Clinical)33 herein, were prepared as described previously51 and stored at -80 ◦C
before use.
Prior to extensional flow experiments, proteins were thawed on ice and buffer-exchanged into filtered (0.22 μm pore
size, Millipore, Ireland) and de-gassed buffer (25mMHEPES {Sigma-Aldrich, St. Louis}, 150mM sodium chloride {Fisher
Scientific, UK}, pH 7.3), using 3.5 kDaMW cut-off dialysis tubes (Generon, UK). Following dialysis, samples were filtered
through 0.22 μm pore size syringe filters (Biofil, China) and their concentrations determined using UV-visible spec-
troscopy, using a typical 150 kDa IgGmolar extension coefficient of 𝜀280 ∼ 210 000M−1 cm−1 63 and their respective relative
molecular masses (Supplementary Table II).
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These stock solutions were diluted to a final concentration of 0.5mgmL−1 and incubated on ice for a maximum of
three hours, until required.
2.2 EFD experiments
Thedesign, validation, and experimental details of theEFDare described elsewhere. 59,60 Briefly, the device consists of two,
1mL syringes (Hamilton, 1001 RN model) connected by a 75mm long, borosilicate glass capillary (Sutter Instruments,
B100-30-7.5 HP). The 15:1 difference in diameter between the syringe and capillary (inner diameters = 4.61 and 0.3mm,
respectively) generates an extensional flow at the contraction point, followed by shear flow along the capillary (Figure 1A).
The syringes were washed sequentially with 2% (v/v) Hellmanex-III solution (Hellma Analytics, Germany), 18MΩ H2O
and filtered buffer prior to introduction of each sample. 0.5mL of protein solutionwas drawn slowly through the capillary
into one syringe. Ensuring removal of air bubbles, the syringes were clamped and connected. Using a steppermotor driver
slideway, the syringes were driven at a velocity of 8mms−1 for 200 passes (where one pass is defined as the emptying of
one syringe and the refilling of the other) at ambient temperature. A control quiescent sample was incubated at ambient
temperature for the duration of the flow experiment (200 passes at 8mms−1 takes ∼20minutes). Following stress, the
syringes were disassembled and the protein solution decanted slowly into an Eppendorf tube through the capillary. All
experiments were performed in duplicate.
2.3 Pelleting assay to quantify insoluble protein
A pelleting assay (Figure 1B) was performed as described previously.59,60 Briefly, 2× 200 μL of protein sample (stressed
or quiescent) were clarified by ultra-centrifugation using a Beckmann Coulter Optima Ultracentrifuge, equipped with
a TLA100 rotor (30 000 rpm [∼35 000g] for 30min at 4 ◦C). Hundred and fifty microliters of supernatant were removed
from each tube, leaving 50 μL of pellet fraction. Two hundred microliters of denaturing buffer (50mM Tris HCl (Fisher
Scientific, China), 6M guanidine hydrochloride, pH 6 (SigmaAldrich, Germany)was added to both the pellet fraction and
to 50 μL of the supernatant. Each 250 μL (total volume) sample was then incubated overnight at 4 ◦C to ensure all proteins
were denatured. The concentration of protein in each fraction was then determined using UV-visible spectroscopy at
280 nm, using the extinction coefficient described above. The % protein in pellet (ie, extent of aggregation) was calculated
using Equation (1):
%protein in pellet =
(
([P] − [S])
([protein]0)
)
× 100 (1)
Quantification of% protein in pelletwhere [P], [S], and [protein]0 are the concentration of protein in the pellet fraction,
[S] supernatant fraction and initial protein solution, respectively.
The average % protein in pellet was calculated for each set of technical replicates, with the SD (error) then
estimated. The final mean and error (SD) for the two biological repeats, C± 𝛿C, was calculated according to
Equation (2):
𝛿𝐶
C =
√(
𝛿𝐴
A
)2
+
(
𝛿𝐵
B
)2
(2)
Error propagation equation between replicates where A =mean of replicate A, B =mean of replicate B, 𝛿A = SD
from replicate A, 𝛿B = SD from replicate B. The equation is rearranged and solved for 𝛿C (the propagated
error).
2.4 Therapeutic aggregation profiler (TAP) analysis
TAP metric values were obtained from the TAP webserver (http://opig.stats.ox.ac.uk/webapps/newsabdab/sabpred/
tap).64 The VH and VL sequences of fezakinumab and figitumumab (from Jain et al51) were inputted manually into
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the webserver. A flag was awarded to a mAb for every TAP guideline threshold that was exceeded (updated 16th
June 2019, Supplementary Table III). The number of flags awarded was plotted against the % protein in pellet for the
(Clinical)33.
2.5 Other in silico methods
Details regarding homology model building, isoelectric point (pI) and complementarity determining region (CDR) net
charge determination, quantification of intrinsic, and structure-corrected solubility using CamSol and APR identification
using Solubis, are available in the Supplementary Methods.
Statistical analysis of flow-induced aggregation data: Statistical analyses were performed on the mAb data in R (Ver-
sion 3.4.4) as described previously.51 Red flags for each mAb were assigned based on thresholds determined previously51
and used to construct box plots of % protein in pellet vs the violations for each assay. Spearman's rank correlations to com-
pare assay relatedness were performed as described previously.51 Briefly, the pairwise correlation matrix (excluding and
including the EFD) was used as input to an agglomerative hierarchical clustering algorithm with average linkage crite-
rion for determining cluster distance. This yielded five main assay groups: 1 (PSR {Poly-specificity reagent}, CSI {Clone
self-interaction by biolayer interferometry}, and AC-SINS {Affinity capture- self interaction nanoparticle spectroscopy}), 2
(HIC {Hydrophobic interaction chromatography}, SMAC {Standup monolayer adsorption chromatography}, SGAC-SINS
{Salt-gradient AC-SINS}, and CIC {Cross-interaction chromatography}), 3 (BVP {Baculovirus particle} and multiantigen
ELISA {Enzyme-linked immunosorbent assay}), 4 (AS {Accelerated stability, using size-exclusion chromatography to
assess monomer loss}), and 5 (HEK {Expression titer in HEK293 cells} and Tm {apparent Tm by Differential Scanning Flu-
orimetry}). When EFD was included in the analysis, it manifested as a distinct sixth group in the clustering analysis (see
main text).
To assess the robustness of the analysis to the error in the EFDmeasurements, bootstrapping analysis was performed.
One of the two extensional flow experimental values for each of the 33 sampleswas picked randomly. The correlation coef-
ficient was calculated for this set of values against the 12 developability assays and five in silico metrics. This calculation
was repeated 10 000 times to obtain the median and 95% confidence intervals (Supplementary Table IV).
3 RESULTS
3.1 Subjecting mAbs to defined hydrodynamic flows reveals diverse aggregation
behavior
We have shown previously that mAbs are more sensitive to extensional and shear flows than proteins with other folds
such as Bovine Serum Albumin (BSA), Granulocyte-colony Stimulating Factor (G-CSF) and 𝛽2-microglobulin (𝛽2m).59,60
A subset of 33 mAbs from 137 in the original dataset51 were selected from across the clusters of mAbs grouped previ-
ously by their biophysical properties.51 Twelve of the molecules were derived from approved antibodies, nine from Phase
III and twelve from phase II. This group of antibodies, dubbed the (Clinical)33 herein, showed varied responses in the
assays employed previously (Supplementary Table I and Figure S1).51 Themagnitude of aggregation triggered by the EFD
is strongly dependent on protein concentration, strain rate (which is controlled by changing the velocity of the syringe
driver) pass number (the number of times the fluid is shuttled through the capillary) and solution conditions (eg, arginine
succinate buffer suppressing flow-induced aggregation), yielding a complex response surface to flow.60 Here, the large
number of antibodies to be studied, together with sample limitations, precluded such a detailed study. Instead, informed
by previous studies,60 we chose a single condition (200 passes at a plunger velocity of 8mms−1 {strain rate = 11 750 s−1,
shear rate = 52 000 s−1}) predicted to yield moderate aggregation levels (∼40% at 0.5mgmL−1) for a “bioprocessible”
mAb such as MEDI1912_STT.60 All 33 mAbs were stressed under common solution conditions (mAb concentration of
0.5mgmL−1, formulated in HEPES-buffered saline [Methods]) and the level of aggregation was assessed by pelleting the
samples at 35 000g for 30minutes, then quantifying the protein concentration in the pellet and supernatant after overnight
solubilization and denaturation in 6M guanidine hydrochloride (Figure 1B and Methods). The data (Figure 2A, B) show
that the EFD-induced aggregation of the mAbs covers a wide dynamic range (9-81% protein in the pellet). Given the rel-
atively large error (7% average propagated error) the extent of aggregation of each mAb was classified as low, medium or
high (0-20%, 21-60% and >60% protein in pellet, respectively).
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F IGURE 2 Quantification of EFD-induced protein aggregation
for the (Clinical)33 mAbs. (A) The percentage of mAb that was
pelleted by ultra-centrifugation after exposure to defined
hydrodynamic forces. The mAb samples (at 0.5mgmL−1 in 25mM
HEPES+ 150mM sodium chloride, pH 7.3) were stressed for 200
passes at a plunger velocity of 8mms−1. Samples were then analyzed
using the protein pelleting assay (Methods). Error bars represent the
propagated error from two independent experiments. (B) Spread of
the average protein in pellet data for the (Clinical)33 mAbs stressed in
the EFD (closed diamonds) and measured following quiescent
incubation (open diamonds). The average experimental error was 7
and 3% for flow and quiescent samples, respectively
Few mAbs in the dataset (6/33) fall into the last, poor behavior category, a trend observed for many of the assays
employed previously.51 This large range of flow-induced aggregation is not observed under quiescent conditions (1± 3%
[SD] protein in pellet, Figure 2B) and the relative levels under flow and quiescent conditions are uncorrelated (Figure
S2). This demonstrates that EFD-induced aggregation does not simply measure native-state aggregation, which for these
proteins is minimal over this relatively short timescale. Furthermore, the data suggest freeze-thaw stresses, encountered
by the molecules in the (Clinical)33, do not contribute to the observed aggregation behavior. Interestingly, the data show
a broad response to hydrodynamic flow across the 33 samples, despite the fact the dataset comprises antibodies made
with variable domain sequences sourced from mAbs that reached late stages of development or even approval. It should
be noted, however, that to facilitate their expression, purification, and ease of comparison, each variable domain pair was
grafted onto a common IgG1 isotype and analyzed in a single buffer. While containing sequences from “developable”
molecules, these mAbs are not optimally formulated.
3.2 Can bioinformatics tools rationalize the EFD data?
After showing that EFD-induced aggregation is unrelated to quiescent behavior, we next sought to ascertain whether
in silico biophysical metrics correlated with flow-induced aggregation (Methods and Supplementary Methods). The
recently developed TAP algorithm,64 which was partly trained on the Jain et al dataset,51 was used to identify unde-
sirable CDR features in the (Clinical)33 which could rationalize increased aggregation under flow. No clear correlation
between the number of TAPmetric flags and increased aggregation in the EFDwas observed (Figure 3 and Supplementary
Table III).
Further in silico analyses of the (Clinical)33, including: pI65 and CDR net charge analysis,66 innate and
structure-corrected solubility by CamSol34,35,49 and APR identification by Solubis,26 were unable to discern clear correla-
tions between the biophysical parameters of the sequences under investigation and their aggregation following stress in
the EFD (Supplementary Table IV and Figures S3-S6, respectively). We have shown previously that flow-induced aggre-
gation of BSA occurs concurrently with the exposure of a cysteine residue, whose side-chain is buried in the native state.59
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F I GURE 3 Correlation of Therapeutic Antibody Profiler (TAP)
developability flags with EFD-induced aggregation data (from Figure 2a) for the
(Clinical)33. Box plot boundaries are the 25th and 75th percentiles, with the
median bisecting the box. Only 21% of the (Clinical)33 dataset possessed one or
more flags following TAP analysis (Methods). Some mAbs are shown to be
aggregation-prone under flow despite possessing 0 or 1 flag(s). The mAb with
two amber flags is galiximab, whilst that with three amber flags is
cixutumumab. Threshold values for the TAP guideline flags (updated 16th June
2019) are presented in Supplementary Table III
Prediction of the extent of flow-induced aggregation by in silico approaches may thus require a better understanding of
the relationship between flow fields and local protein stabilization, the study of which is in its infancy.67
3.3 How do the EFD data relate to those from alternative biophysical techniques?
Wehave demonstrated that EFD-induced aggregation of the (Clinical)33 cannot be predicted by simple biophysical and/or
structural parameters, suggesting the EFD may have a novel role in the identification of developable candidates. It has
been shown recently, however, that there is redundancy amongst current developability assays.51,68 To understand the
relationship between the EFD and other methods commonly used to assess mAb developability, we compared the out-
puts from the EFD with the 12 biophysical techniques used previously51 (see Methods for full list). To allow comparison
across different assays, Jain et al51 identified values for 10 of the methods (the bottom 10% of long-tailed distributions,
termed a red flag), below which a mAb would be identified as potentially problematic. The data for the expression
titer from HEK293 cells and the apparent Tm of the Fab obtained using differential scanning fluorimetry for the 137
mAbs, were normally distributed and were thus excluded from the red flag analysis.51 Comparison of the distribution of
EFD-induced aggregation observed for those mAbs that passed the selection criteria for each technique, with those that
failed (red-flagged mAbs), revealed that no single assay was highly predictive of high EFD-induced aggregation (Figure
S7a-j). Assays belonging to the poly-specificity and ELISA clusters showed generally higher average EFD-induced aggre-
gation for mAbs with red flags. No strong relationship was observed between the level of flow-induced aggregation and
the number of red flags awarded to each mAb (Figure S7k), similar to the TAP data in Figure 3. Analysis of these data
by Spearman's rank correlation coefficients, showed that mAbs which aggregated to the greatest extent under flow per-
formed worst in the assays which probed poly-specific aggregation, such as AC-SINS, PSR, CSI and multiantigen ELISA
(Supplementary Table IV), confirming the trends observed in the red flag analysis.
Finally, the relationship between the data obtained from the EFD and other developability assays was assessed using
hierarchical clustering (Methods). The results (Figure 4) show that the EFD has a distinct branch on the “family tree” of
assays assessed in the (Clinical)33 dataset. This suggests that the EFD probes a unique feature of mAbs and that protein
aggregation induced by the EFD is distinct to the aggregation/association mechanisms probed by other assays.
4 DISCUSSION
Despite the therapeutic and commercial success of mAbs,11 a significant effort is still required by industrial and aca-
demic laboratories to rapidly assess and better predict the “developability” of these molecules29,49,51,69,70 and their more
complex derivatives, such as antibody-drug conjugates71 and bispecifics.72 Commercially, this approach should reduce
cost of goods and decrease time to market. The increasing number of in vitro and in silico “developability” tools, in
conjunction with the potentially large panel of molecules to screen, has led to the need to understand how different
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F IGURE 4 Hierarchical clustering “family trees” of assays used to probe the biophysical properties and developability of mAbs. The
tree on the left shows the clustering data for the (Clinical)33 mAbs without the flow data. The tree on the right shows the clustering data for
(Clinical)33 mAbs when extensional flow is included as an assay (EFD, red box). Assays are color coded according to the assay groups from
Jain et al51 (Methods)
assays relate to one another, which biophysical features of molecules these assays probe and how combining these tech-
niques increases knowledge about a mAb's developability.3,30,47,73 This is particularly harmonious with the “Quality by
Design” framework.74 Jain et al addressed this need by subjecting a panel of mAbs to a broad range of typically deployed
assays to create a reference dataset.51 These data enable the assessment of emerging techniques and their relationship to
established methods, using mAbs that vary only in the variable domains in common solution conditions (hence without
formulation).49,64,66,70,75,76
The potential for hydrodynamic forces to induce mAb aggregation has long been of concern,9 with fresh attention
being paid recently.77-80 Our efforts to address this inspired design of the EFD and its application to three IgG1s.59,60 With
the above inmind, we set out to analyze the extent of EFD-induced aggregation for a subset of 33mAbs from the Jain et al
dataset. The (Clinical)33 mAbs showedwide-ranging extents of aggregation under identical experimental conditions in the
EFD. Importantly, such data were obtained using just 1mg of material per antibody. Whilst manymAbs are administered
at concentrations >100mg/mL,81 we performed our measurements at 0.5mgmL−1 in order to best compare the results
from this study with both previous EFD studies and the Jain et al dataset. Furthermore, the use of small quantities of
material in the EFD allows it to be used efficiently alongside an array of developability methods. We also emphasize
that the aim of this study was to make comparisons between the EFD data and those from other datasets, as opposed to
studying all the molecules in their patented formulations.
Some mAbs, with favorable “manufacturable” attributes (ie, they received 0 or 1 “red flags” in the developability
assays),51such as those with Fv sequences from alemtuzumab and tralokinumab were found to be sensitive to hydro-
dynamic forces, while others (eg, Fv sequences from etrolizumab and dalotuzumab) showed the opposite behavior.
We also showed that commonly employed in silico methods cannot act as a surrogate for experimental measurements
of flow-induced aggregation propensity. We have previously shown that extensional flow triggers partial unfolding of
BSA,59 which may expose APRs that are sequestered from solvent in the thermodynamically stable native protein
(ΔGUN = 15.2 kJmol−1),82 thereby evading detection by both CamSol and Solubis. In this regard, it is interesting to note
that many of the APRs predicted by Solubis26 are found on theVH-VL interface or the CDRH3 loop (Figure S6b). Bioinfor-
matics analysis has shown that this interface is less polar than the surface of antibody fragments.83 Whilst such regions are
buried in staticmodels, innate46,84 or flow-induced dynamicsmay exposeAPRs to the solvent, explaining the lack of corre-
lation between the EFD and in silico predictions. The apparent lack of predictive power of these in silico methods26,34,49,64
for the effects of flow may be because the mechanism of flow-induced aggregation is different to those used to train these
algorithms.
It has been suggested by others (including a reviewer) that hydrodynamic forces cannot induce aggregation.57,79,85
Whilst many agree that shear flow alone does not induce aggregation, the effects of extensional flows on proteins
have largely been neglected by the field. Simon et al86 used a four-roll mill device to trigger protein aggregation under
extensional flows. Using an array of proteins, including three IgG1mAbs, we have also showed that extensional (and sub-
sequent shear) flow induced by the EFD can trigger protein aggregation and that these effects were extremely protein-
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and flow-field specific.59,60 More recently, EFDs of similar design to that employed in our study have been constructed
and mAb aggregation observed under extensional and shear flows.87,88 These and other studies57,79,85,89-93 have shown
that the presence and chemical composition of interfaces and presence of localized high protein concentrations within
flow devices also contribute to the aggregation cascade. Others have suggested that the friction between the solid com-
ponents of flow devices, for example, Couette cylinders89 or plungers and syringe barrels, can also induce aggregation.
The relative importance of stain rate, surface chemistry, and friction for EFD-induced protein aggregation is beyond the
scope of this study.
The aim of this study was not to understand the molecular mechanism of EFD-induced aggregation but to investi-
gate the relationship between the EFD and other commonly employed developability assays. The results presented show
that the EFD induces a wide-range of aggregation response that is not correlated with other metrics of developability as
demonstrated by hierarchical clustering. In response to a reviewer, we have used bootstrapping analysis to show that the
clustering is statistically significant, despite an average error of±7% for the EFD data. As such, the EFDmay reveal a new
critical quality attribute that must be met for a candidate mAb to proceed to development.
The EFD could thus allow poorly behaving candidates to be identified early in the development pipeline. Moreover,
by varying the flow conditions and the solution properties, the EFD can be used to select mAbs that are resilient to
flow stresses.60 This information could be taken into late-stage development, allowing manufacturing conditions and/or
formulations to be changed to suppress the aggregation of the molecule under hydrodynamic forces.60 Such information
cannot be gleaned from currently available assays or in silico methods. Similarly to other assays,19,55 the ability to predict
long-term stability and the relationship between the EFD data and accelerated stability is still to be determined. Overall,
the EFD could help industry screen molecules and accelerate the selection of promising candidates to be taken forward
for biomanufacture.
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